Clearside Biomedical (CLSD) Price & Analysis

Compare

1,051 Followers

CLSD Stock Chart & Stats

Day’s Range― - ―

52-Week Range$0.29 - $1.65

Previous CloseN/A

Volume106.43K

Average Volume (3M)759.36K

Market Cap

$26.39M

Enterprise Value$109.13M

Total Cash (Recent Filing)$9.38M

Total Debt (Recent Filing)$533.00K

Price to Earnings (P/E)―

Beta1.14

Next Earnings

Nov 18, 2025

EPS Estimate

-0.07

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-0.10

Shares Outstanding78,510,315

10 Day Avg. Volume717,110

30 Day Avg. Volume759,359

Financial Highlights & Ratios

PEG RatioN/A

Price to Book (P/B)N/A

Price to Sales (P/S)N/A

P/FCF RatioN/A

Enterprise Value/Market Cap4.14

Enterprise Value/Revenue26.20

Enterprise Value/Gross Profit29.62

Enterprise Value/Ebitda-6.02

Forecast

1Y Price Target

$2.50

Price Target Upside657.58% Upside

Rating ConsensusHold

Number of Analyst Covering6

Bulls Say, Bears Say

Bulls Say

Positive Trial ResultsThe Phase 2b ODYSSEY trial of CLS-AX in wet AMD reported positive topline results, maintaining stable BCVA and CST from baseline to Week 36.

Strategic AlternativesCLSD announced plans to explore a full range of strategic alternatives with an investment bank to advance its CLS-AX program and maximize shareholder value.

Bears Say

Funding ChallengesCLSD is facing difficulties in securing funding or partnerships to advance its CLS-AX program into phase 3 development.

Operational ChangesAll internal research and development programs will pause during this process of exploring strategic alternatives.

Clearside Biomedical News

Clearside Biomedical Announces Reverse Stock Split Plan

The latest update is out from Clearside Biomedical ( ($CLSD) ). On September 10, 2025, Clearside Biomedical, Inc....

4h ago

CLSD

Clearside Biomedical Announces Reverse Stock Split

An update from Clearside Biomedical ( ($CLSD) ) is now available. On September 10, 2025, Clearside Biomedical, Inc....

4h ago

CLSD

Clearside Biomedical Secures $3M with Agreement Amendment

Clearside Biomedical ( ($CLSD) ) just unveiled an announcement. On September 4, 2025, Clearside Biomedical, Inc. amended its...

3d ago

CLSD

Clearside Biomedical Approves Reverse Stock Split Proposal

Clearside Biomedical ( ($CLSD) ) has shared an update. On August 28, 2025, Clearside Biomedical received a notice...

8d ago

CLSD

CLSD Earnings this Week: How Will it Perform?

Clearside Biomedical Inc (CLSD) is scheduled to report 2nd quarter earnings on 08/18/2025. Regarding Q2 estimates, Wall Street...

26d ago

CLSD

Clearside Biomedical Announces New Chairperson Appointment

Clearside Biomedical ( ($CLSD) ) has shared an announcement. On February 7, 2025, Clearside Biomedical was notified by...

28d ago

CLSD

Hold Rating on Clearside Biomedical Amid Financial Uncertainty and Strategic Exploration

JonesTrading analyst Debanjana Chatterjee has maintained their neutral stance on CLSD stock, giving a Hold rating on July...

1M ago

CLSD

Clearside Biomedical’s Phase 2b Study on CLS-AX: A New Hope for AMD Treatment

Clearside Biomedical Inc (($CLSD)) announced an update on their ongoing clinical study. Clearside Biomedical Inc. recently completed a...

2M ago

CLSD

Clearside Biomedical announces approval of XIPERE in Canada

Clearside Biomedical (CLSD) announced that Health Canada has granted approval for XIPERE for suprachoroidal use in the treatment...

2M ago

CLSD

Snowflake initiated, Chipotle upgraded: Wall Street’s top analyst calls

The most talked about and market moving research calls around Wall Street are now in one place. Here...

2M ago

ABT

Clearside Biomedical downgraded to Neutral from Buy at H.C. Wainwright

H.C. Wainwright downgraded Clearside Biomedical (CLSD) to Neutral from Buy without a price target after the company said...

2M ago

CLSD

Clearside Biomedical downgraded to Neutral from Buy at Chardan

Chardan analyst Daniil Gataulin downgraded Clearside Biomedical (CLSD) to Neutral from Buy without a price target after the...

2M ago

CLSD

Clearside Biomedical downgraded to Hold from Buy at Stifel

Stifel downgraded Clearside Biomedical (CLSD) to Hold from Buy with a price target of $2, down from $8....

2M ago

CLSD

Clearside Biomedical Downgraded to Hold Amid Strategic and Financial Uncertainties

Stifel Nicolaus analyst Annabel Samimy downgraded the rating on Clearside Biomedical to a Hold today, setting a price...

2M ago

CLSD

CLSD FAQ

What was Clearside Biomedical’s price range in the past 12 months?

Clearside Biomedical lowest stock price was $0.29 and its highest was $1.65 in the past 12 months.

What is Clearside Biomedical’s market cap?

Clearside Biomedical’s market cap is $26.39M.

When is Clearside Biomedical’s upcoming earnings report date?

Clearside Biomedical’s upcoming earnings report date is Nov 18, 2025 which is in 68 days.

How were Clearside Biomedical’s earnings last quarter?

Clearside Biomedical released its earnings results on Aug 18, 2025. The company reported -$0.1 earnings per share for the quarter, missing the consensus estimate of -$0.091 by -$0.009.

Is Clearside Biomedical overvalued?

According to Wall Street analysts Clearside Biomedical’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Clearside Biomedical pay dividends?

Clearside Biomedical does not currently pay dividends.

What is Clearside Biomedical’s EPS estimate?

Clearside Biomedical’s EPS estimate is -0.07.

How many shares outstanding does Clearside Biomedical have?

Clearside Biomedical has 78,510,315 shares outstanding.

What happened to Clearside Biomedical’s price movement after its last earnings report?

Clearside Biomedical reported an EPS of -$0.1 in its last earnings report, missing expectations of -$0.091. Following the earnings report the stock price went same 0%.

Which hedge fund is a major shareholder of Clearside Biomedical?

Currently, no hedge funds are holding shares in CLSD

Clearside Biomedical Stock Smart Score

Neutral

Fundamentals

Return on Equity

91.63%

Trailing 12-Months

Asset Growth

-54.82%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

Clearside Biomedical

Clearside Biomedical, Inc. is a biopharmaceutical company focused on developing innovative therapies for treating serious eye diseases. The company operates primarily in the ocular therapeutics sector, leveraging its proprietary drug delivery platform, the SCS Microinjector, to enhance the delivery of therapeutics directly to the suprachoroidal space of the eye. Clearside's core products include its lead asset, Xipere (triamcinolone acetonide injectable suspension), approved for the treatment of macular edema associated with uveitis, as well as a pipeline of product candidates aimed at various ocular conditions.

Clearside Biomedical (CLSD) Earnings & Revenues

Historic Earnings Reports

CLSD Stock 12 Month Forecast

Average Price Target

$2.50

▲(657.58% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"4":"$4","-1":"-$1","0.25":"$0.25","1.5":"$1.5","2.75":"$2.75"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":3,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$3.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":2.5,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$2.50</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":2,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$2.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[-1,0.25,1.5,2.75,4],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Dec<br/>2024","6":"Mar<br/>2025","9":"Jun<br/>2025","12":"Sep<br/>2025","25":"Sep<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,0.34,0.5446153846153846,0.7492307692307693,0.9538461538461538,1.1584615384615384,1.363076923076923,1.5676923076923077,1.7723076923076924,1.976923076923077,2.1815384615384614,2.386153846153846,2.5907692307692307,2.795384615384615,{"y":3,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,0.34,0.5061538461538462,0.6723076923076923,0.8384615384615385,1.0046153846153847,1.1707692307692308,1.3369230769230769,1.5030769230769232,1.6692307692307693,1.8353846153846154,2.0015384615384613,2.167692307692308,2.333846153846154,{"y":2.5,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,0.34,0.46769230769230774,0.5953846153846154,0.7230769230769232,0.8507692307692307,0.9784615384615385,1.1061538461538463,1.2338461538461538,1.3615384615384616,1.4892307692307694,1.616923076923077,1.7446153846153847,1.8723076923076925,{"y":2,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":1.01,"date":1725148800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.34,"date":1727740800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.01,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.09,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 9, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.95,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 10, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.93,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.86,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.91,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.85,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 18,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 4</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.74,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 5</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.79,"date":1751328000000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 15, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 6</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":0.38,"date":1754006400000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 14, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 5</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":0.34,"date":1756684800000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 13, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 4</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >